An open-label, 6-month study of allopurinol safety in gout: The LASSO study

Abstract

This large multicenter study found that the allopurinol dose-titration strategy was well tolerated, without new safety signals emerging over 6 months. However, despite encouragement to treat to target, significant proportions of patients did not achieve target sUA.